secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001628280-23-040546
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target
--------------------------------------------------------------------------------

- Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.
- Total deal consideration up to $247M, including upfront, R&D funding, milestones, plus royalties on sales.
- Agreement combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
- Platform aims to reduce drug design-validation cycle to ~6 weeks and expand target universe to GPCRs, ion channels.
- Collaboration follows Absci's recent publication on 'zero-shot' generative AI model for de novo antibody design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/0001628280-23-040546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/absc-20231204.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-040546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer